Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Naslov
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Identifikator
/unibl/sci/idNaucniRad:24619
Tip
Pronađite slične unoseAcademic Article
Datum
Pronađite slične unose2016-09
Bibliografski citat
W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, pp. 100 - 101, Sep, 2016
Početna stranica
100
Krajnja stranica
101
Je dio
STED Journal
2637-2150
Lista autora
Position: 20702 (39 views)